Physicochemical Properties
| Molecular Formula | C38H59CLN4O7S |
| Molecular Weight | 751.415668725967 |
| Exact Mass | 750.379 |
| CAS # | 1835705-55-9 |
| PubChem CID | 129072788 |
| Appearance | Light yellow to yellow ointment |
| LogP | 4.9 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 25 |
| Heavy Atom Count | 51 |
| Complexity | 1010 |
| Defined Atom Stereocenter Count | 3 |
| SMILES | CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCOCCOCCOCCCCCCCl)O |
| InChi Key | MLRLOIWXHCPWFF-MEEYNGGZSA-N |
| InChi Code | InChI=1S/C38H59ClN4O7S/c1-28-34(51-27-41-28)30-15-13-29(14-16-30)25-40-36(46)32-24-31(44)26-43(32)37(47)35(38(2,3)4)42-33(45)12-8-7-11-19-49-21-23-50-22-20-48-18-10-6-5-9-17-39/h13-16,27,31-32,35,44H,5-12,17-26H2,1-4H3,(H,40,46)(H,42,45)/t31-,32+,35-/m1/s1 |
| Chemical Name | (2S,4R)-1-[(2S)-2-[6-[2-[2-(6-chlorohexoxy)ethoxy]ethoxy]hexanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | (S,R,S)-AHPC-C6-PEG3-C4-Cl employs the cereblon ligand [1]. The linker is 6-2-2-6. The linkers comprise a combination of hydrophobic and hydrophilic moieties that balance the hydrophobicity and hydrophilicity of the resulting hybrid molecules. PROTACs that cause the degradation of BCR-ABL, an oncogenic tyrosine kinase, have been created. (S,R,S)-AHPC-C6-PEG3-C4-Cl can be linked to potent TKIs (bosutinib and dasatinib), which degrade c-ABL and BCR-ABL by hijacking either the CRBN or VHL E3 ubiquitin ligase [2]. |
| References |
[1]. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. [2]. US 20170121321 A1. |
Solubility Data
| Solubility (In Vitro) |
Ethanol : ~100 mg/mL (~133.08 mM) DMSO : ≥ 100 mg/mL (~133.08 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3308 mL | 6.6541 mL | 13.3081 mL | |
| 5 mM | 0.2662 mL | 1.3308 mL | 2.6616 mL | |
| 10 mM | 0.1331 mL | 0.6654 mL | 1.3308 mL |